Document is current
Any future updates will be listed below
-
Authors
Fragoso-Saavedra, Sergio
Núñez, Isaac
Audelo-Cruz, Belem M.
Arias-Martínez, Sarahi
Manzur-Sandoval, Daniel
Quintero-Villegas, Alejandro
Benjamín García-González, H.
Carbajal-Morelos, Sergio L.
PoncedeLeón-Rosales, Sergio
Gotés-Palazuelos, José
Maza-Larrea, José A.
Rosales-de la Rosa, J. Javier
Diaz-Rivera, Dafne
Luna-García, Edgar
Piten-Isidro, Elvira
Del Río-Estrada, Perla M.
Fragoso-Saavedra, Mario
Caro-Vega, Yanink
Batina, Isabella
Islas-Weinstein, León
Iruegas-Nunez, David A.
Calva, Juan J.
Belaunzarán-Zamudio, Pablo F.
Sierra-Madero, Juan
Crispín, José C.
Valdés-Ferrer, Sergio Iván https://orcid.org/0000-0002-4863-6484
-
Funding
Funding for this research was provided by:
Consejo Nacional de Ciencia y Tecnología (311790, A1-S-18342)
- License Information
-
More Information
Article History
Received: 1 June 2022
Revised: 5 September 2022
Accepted: 3 October 2022
First Online: 8 November 2022
Declarations
:
: This study was conducted following the recommendations of the institutional Ethics in Human Research Committees. All participants had given written informed consent to one of the study investigators under the Declaration of Helsinki. The protocol was approved by the Ethics in Human Research Committees of <i>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</i> (INCMNSZ), and <i>Instituto Nacional de Cardiología Ignacio Chávez</i>, both located in Mexico City, Mexico; and <i>Comisión Federal para la Protección contra Riesgos Sanitarios</i> (COFEPRIS), the Federal Mexican pharmacological regulatory commission.
: SIVF via Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán appears as inventor for a repurpose patent for the use of pyridostigmine in COVID-19. SIVF, and JCC are members of the Molecular Medicine Editorial Board.
: Not applicable.
: ClinicalTrials.gov, identifier: NCT04343963.
